Active Filter(s):
Details:
The proceeds will advance company's lead clinical asset, ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2, in registrational-intent Phase 2 trials, as well as its preclinical pipeline including ACR-2316, a novel WEE1/PKMYT1 inhibitor.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Product Name: ACR-368
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 09, 2024
Details:
Acrivon is currently advancing its lead candidate, ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Product Name: ACR-368
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $99.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 15, 2022
Details:
Proceeds will support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Damage Response (DDR) inhibitor clinically validated in solid cancers, and in-house drug pipeline driven by the company’s proprietary platform technology.
Lead Product(s): Prexasertib
Therapeutic Area: Oncology Product Name: ACR-368
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Wellington Management Company
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 11, 2021
Details:
Acrivon intends to develop prexasertib (also called ACR-368) in accelerated clinical trials treating patients whose tumors are driven by, and depend on, dysregulated CHK1 and CHK2 using the OncoSignature® test.
Lead Product(s): Prexasertib
Therapeutic Area: Oncology Product Name: ACR-368
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021